Want to see TCRX full AI Analyst Report?
TCRX Stock Chart & Stats
$1.19
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.19
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.83 - $2.57
Previous CloseN/A
Volume150.47K
Average Volume (3M)476.93K
Market Cap
$59.78M
Enterprise Value$95.69
Total Cash (Recent Filing)$128.06M
Total Debt (Recent Filing)$92.54M
Price to Earnings (P/E)―
Beta1.99
Next Earnings
Aug 19, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding61,074,230
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside404.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.03
Revenue Forecast (FY)$7.86M
Bulls Say, Bears Say
Bulls Say
Clinical & Manufacturing ProgressConsistent manufacturing success (~90%) and rapid biological responses (11/14 complete donor chimerism) materially de-risk the TSC-101 program. Operational readiness and investigator engagement improve prospects for a smooth transition to a pivotal Phase 3, reducing late-stage execution risk and supporting scalable commercial manufacturing.
High Gross MarginsA very high reported gross margin (~92%) indicates that when products or partnered revenues materialize, underlying unit economics could be attractive. For cell therapy platforms this suggests potential for sustainable margin capture and better long-term profitability once scale and reimbursement are established.
Manageable LeverageLeverage appears moderate for an early-stage biotech, with debt-to-equity near 0.62 and positive equity. This balance-sheet position preserves access to multiple financing options and strategic partners, providing financial flexibility to advance clinical programs before needing immediately dilutive measures.
Bears Say
High Cash BurnSustained operating and free cash outflows near -$122M/-$125M TTM create a persistent funding requirement. Over the medium term this forces reliance on external capital, heightens dilution risk, and constrains strategic optionality if clinical timelines slip or additional studies are required before revenue generation.
Weak And Declining RevenueModest, falling revenue (~$9.1M, -11.5% YoY) underscores the absence of recurring product sales and reliance on collaborations or one-time funding. This unstable top line reduces internal self-funding capacity and increases sensitivity to financing markets, making sustained development dependent on external capital or partnerships.
Elevated Dilution CapacityApproval to double authorized shares materially expands the company's capacity to issue equity. Combined with a weakened equity base versus prior year, this increases the probability of meaningful dilution to fund operations or partnerships, potentially diluting existing investors and affecting long-term share economics.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.82 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $59.78M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 30 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.018.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 61,074,230 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went up 3.306%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (404.20% Upside)
$6.00 (404.20% Upside)
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.14%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.29%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(404.20% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
17.47% Insiders
5.44% Mutual Funds
32.09% Other Institutional Investors
41.26% Public Companies and
Individual Investors